Hatter Horizon Series 2018: Multimedia

Monday 10th December 2018

Videos of the presentations will be posted where when available.

Reducing the global burden of diabetes & cardiovascular disease: is there a role for governments?
Professor Dinky Levitt
University of Cape Town, South Africa


How will genetics impact on prevention and treatment of type 2 diabetes?
Professor Mark McCarthy
Oxford Centre for Diabetes, University of Oxford, UK


The biology and therapeutic potential of GLP-1 - another year on!
Professor Daniel Drucker
University of Toronto, Canada


The biology and therapeutic potential of SGLT2 inhibition - another year on!
Professor Nikolaus Marx
University of Aachen, Germany


SGLT2 Outcome trials - an evolving story
Professor Stephen Wiviott
Brigham & Women's Hospital, Boston, USA


Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes - i.e. weight management?
Professor Melanie Davies
Diabetes Research Centre, University of Leicester, UK


Is it time to rethink HbA1c?
Dr Dev Singh
New Cross Hospital, Wolverhampton, UK


How do SGLT2 inhibitors benefit the kidney?
Professor David Wheeler
University College London


Is there still a place for sulphonylureas?
Professor Cliff Bailey
Aston University, Birmingham, UK


Leave a comment